Osteoporosis drug could be used to treat aggressive form of breast cancer, researchers say

(Rockefeller University Press) Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable. But the study, which will be published May 4 in the Journal of Experimental Medicine, reveals that the widely used osteoporosis drug zoledronic acid inhibits UGT8 and prevents the spread of basal-like breast cancer in mice, suggesting that this drug could also be used to treat the disease in humans.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

In conclusion, fracture risk in postmenopausal women during aromatase inhibitor treatment, in real ‐life conditions, was>40% compared to tamoxifen, corroborating previous randomized controlled trials results. In high ‐risk patients, bisphosphonate users had lower significant fracture incidence during aromatase inhibitor therapy than non‐bisphosphonate‐users. Monitoring fracture risk and related risk factors in aromatase inhibitor patients is advisable.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
ConclusionsDespite an apparently low fracture risk, women under denosumab for AI-treated early-stage breast cancer develop spontaneous VFs at denosumab discontinuation. This risk increases with treatment duration and may be prevented by a potent bisphosphonate.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Menopausal hormone therapy (MHT) is the treatment of choice for menopausal symptoms and urogenital atrophy. Furthermore, it has beneficial effects on chronic diseases related to estrogen deficiency, such as osteoporosis and cardiovascular disease [1 –4]. Women worldwide have been using MHT to alleviate their symptoms for decades. However, fear of breast cancer, hinders menopausal women from seeking medical advice and renders clinicians reluctant to prescribe MHT.
Source: Maturitas - Category: Primary Care Authors: Source Type: research
AbstractPurpose of ReviewThe goal of this review is to summarize recent experimental and clinical evidence for metastatic latency and the molecular mechanisms that regulate tumor dormancy in the bone.Recent FindingsTumor dormancy contributes to the progression of metastasis and thus has significant clinical implications for prognosis and treatment. Tumor-intrinsic signaling and specialized bone marrow niches play a pivotal role in determining the dormancy status of bone disseminated tumor cells. Experimental models have provided significant insight into the effects of the bone microenvironment on tumor cells; however, thes...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Nutritional assessment I Source Type: research
Condition:   Breast Cancer Female, Aromatase Inhibitors, Osteoporosis,QoL, Bone Patology Intervention:   Behavioral: Observational Analysis Sponsor:   Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | China Health | Orthopaedics | Osteoporosis | Reclast | Study | Zometa